Kantar Health Blog

  • Richard Goosey
    Physician interest is declining for participating in market research surveys. Kantar Health has fully embraced the task of improving respondent engagement in our studies and we're proud to talk about two recent successes.
    Continue Reading > | Go comment! | Share
  • World Cancer Day: we can, I can!

    by Otávio Clark | Feb 3, 2017
    Otávio Clark
    On February 4 we observe World Cancer Day, a day created by the Union for International Cancer Control (UICC) aimed at making people all around the world talk about the disease and take actions that can help reduce the impact and weight of diagnosis in families.
    Continue Reading > | Go comment! | Share
  • Opdivo Making Strides in Advanced Hepatocellular Carcinoma

    by Stephanie Hawthorne | Jan 23, 2017
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO GI 2017 --- It is an exciting time for patients and their doctors fighting advanced hepatocellular carcinoma (HCC). In mid-2016 the HCC community witnessed the first randomized trial to successfully improve survival outcomes in Nexavar® (sorafenib, Onyx/Amgen/Bayer)-pretreated HCC when the multikinase inhibitor Stivarga® (regorafenib, Bayer) demonstrated a 38% reduction in the risk of death compared with placebo in the Phase III RESOURCE trial.
    Continue Reading > | Go comment! | Share
  • Opdivo Shows Appetite for Gastric Cancer

    by Jay Grisolano | Jan 20, 2017
    Jay Grisolano
    Oncology Conference Insight: ASCO GI 2017 --- Before Cyramza® (ramucirumab, Eli Lilly and Co) was approved by the FDA in 2014, there were no targeted therapy regimens approved for use in relapsed/refractory gastric cancer. Cyramza’s approval as a monotherapy or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing systemic therapy was based on the positive results of two Phase III studies in relapsed gastric patients.
    Continue Reading > | Go comment! | Share
  • The Patient as a Person

    by Tom Haskell | Dec 13, 2016
    Tom Haskell
    Instead of understanding “the patient,” pharma will need to see “the person who happens to be living with a disease.”
    Continue Reading > | Go comment! | Share